Teva Generic Univasc Patent Victory Vacated
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva plans to continue distributing its generic version of Schwarz' Univasc despite an appeals court's Jan. 29 opinion vacating a noninfringement ruling for the company
You may also be interested in...
Teva Stops Selling Generic Univasc
Agreement with Schwarz ends at-risk launch of the antihypertensive moexipril. Teva launched the generic in May 2003 after receiving a favorable patent ruling in federal district court.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.